Clinical trials and research studies

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-).

The purpose of this clinical trial is to assess the effectiveness of ARIKAYCE, inhaled once daily, in patient populations with mild and untreated MAC lung infection. 

Eligible patients include those who currently have a positive MAC sputum culture and have not received treatment for their infection.

PURPOSE: Endometriosis is an inflammatory disorder in which the tissue that lines the inside of the uterus (the endometrium) spreads to the pelvic and peritoneal cavities outside of the uterus. This is a biological sample collection study examining how bacteria located within the vagina, the urogenital tract and the gastrointestinal tract may affect the development of endometriosis. Investigators are also exploring how an individual’s microbiome affects their estrogen metabolism and inflammation.

This is a local research study to relate heart health and various components found in your body (body fat, sodium, etc.) to high blood pressure during pregnancy, and those with apparently normal blood pressure.

Eligible participants include those with high blood pressure, those receiving treatment for their high blood pressure, women who had high blood pressure during pregnancy, and those with apparently normal blood pressure.

TV50717-CNS-40223: The purpose of this study is to get a better understanding of the disease course of tardive dyskinesia and the impact it has on individuals’ lives. In subjects who may begin on deutetrabenazine (AUSTEDO®) treatment during the study, it will also help investigate the real-world effectiveness of this treatment, particularly on a person’s quality of life.

Improving Outcomes in Vascular Disease – Aortic Dissection

Examining the safety, tolerability, and effectiveness of investigational drug ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia. The study drug will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction

PULMONARY EMBOLISM – THROMBUS REMOVAL WITH CATHETER-DIRECTED THERAPY

The study is designed to identify the best way to treat pulmonary embolism- with blood thinners alone or blood thinners with catheter directed therapy.